Source: Investing.com ↗

Mizuho reiterates Sarepta stock rating after Novartis trial miss

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.02%

BTC/USDT

$85,900.62

-0.08%

ETH/USDT

$2,736.06

-0.30%

ZEC/USDT

$1,659.71

+10.39%

XRP/USDT

$1.59

+3.89%